Latest articles
Maxwellia expand their team with two new appointments
Maxwellia has expanded their team of switch experts with two new appointments following their relocation to the Alderley Park Accelerator.
BMS & Boston Medical Center announce research collaboration
BMS & Boston Medical Center enter research collaboration to investigate markers of immuno-oncology response and resistance Bristol-Myers Squibb Company...
EC approves KEYTRUDA® as adjuvant therapy
MSD (Merck in the U.S. and Canada) has announced that the European Commission has approved its anti-PD-1 therapy, KEYTRUDA (pembrolizumab), for the adjuvant treatment...